Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 11/20 | 0.52 |
| ▸ | ALB | P02768 | 2/20 | 0.52 |
| ▸ | PDE6D | O43924 | 2/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | GRAMD1A | Q96CP6 | 3/20 | 0.43 |
| ▸ | STAT3 | P40763 | 3/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24745226 | 1.00 | MCL1 (0.52) | MCL1ALBPDE6DDDB1CRBN | |
| SCHEMBL24745274 | 0.94 | MCL1 (0.60) | MCL1ALBPDE6DSTAT3BCL2 | |
| SCHEMBL30000879 | 0.94 | MCL1 (0.60) | MCL1ALBPDE6DSTAT3BCL2 | |
| SCHEMBL29262070 | 0.93 | MCL1 (0.61) | MCL1ALBPDE6DBCL2 | |
| SCHEMBL24745172 | 0.92 | PDE6D (0.46) | MCL1ALBPDE6DDDB1CRBN | |
| SCHEMBL24744714 | 0.88 | DDB1 (0.45) | MCL1ALBPDE6DDDB1CRBN | |
| SCHEMBL30000785 | 0.88 | DDB1 (0.45) | MCL1ALBPDE6DDDB1CRBN | |
| SCHEMBL24744722 | 0.87 | GRAMD1A (0.45) | MCL1ALBPDE6DDDB1CRBN | |
| SCHEMBL30000748 | 0.87 | GRAMD1A (0.45) | MCL1ALBPDE6DDDB1CRBN | |
| SCHEMBL24744625 | 0.86 | MCL1 (0.49) | MCL1ALBPDE6D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022255888-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2022-12-08 | — | — | WO | disclosed |